Lundbeck beats forecasts considerably in Q4
In spite of Lundbeck's key product sales retreating the last months of 2020, the pharmaceutical company has profits to show, which vastly exceed the same post from the comparable period last year – and analyst forecasts. The company expects declining revenue in the new year.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
The Covid-19-induced weakening US dollar and competitive market for pharmaceutical producers in 2020's fall and winter have made their mark on Lundbeck's finances.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
